Research Article

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population

Figure 1

Selection of patients eligible for DAPA-HF and EMPEROR-reduced in the Umeå heart failure population when using applicable criteria from the DAPA-HF and EMPEROR-reduced trials. LVEF: left ventricle ejection fraction; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-B-type natriuretic peptide. in patients with recent hospitalization or , <1000 if LVEF 31-35%, and <2500 if LVEF 36-40%; doubled minimum values in patients with atrial fibrillation on latest ECG. , or <400 pg/ml if hospitalization event for heart failure within last 12 months, or<900 pg/ml if last ECG showed atrial fibrillation or flutter.